Arrowhead Pharmaceuticals Files IND to Begin Phase 2b Study of ARO-APOC3 in Patients with Severe Hypertriglyceridemia
Following the FDA’s review of the IND, the company intends to initiate a Phase 2b dose-finding clinical study (ARO-APOC3-2001) in patients with severe hypertriglyceridemia (sHTG). Additional clinical studies planned in 2021 include a Phase 2b dose-finding clinical study in patients with mixed dyslipidemia and a Phase 3 clinical study in patients with familial chylomicronemia syndrome (FCS).
For more information, please visit www.arrowheadpharma.com, or follow us on Twitter @ArrowheadPharma. To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadpharma.com/email-alerts.
Safe Harbor Statement under the Private Securities Litigation Reform Act:
This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the safety and efficacy of our product candidates, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the likelihood and timing of the receipt of future milestone and licensing fees, the future success of our scientific studies, our ability to successfully develop and commercialize drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, and the enforcement of our intellectual property rights. Our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of the important risk factors that may affect our business, results of operations and financial condition. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.